Treatment of Copper Deficiency Myelopathy
Treat copper deficiency myelopathy with copper supplementation at 4-8 mg/day, delivered via oral, enteral, or IV routes depending on severity, and immediately eliminate any causative factors such as excessive zinc intake or malabsorption. 1
Diagnostic Confirmation and Treatment Initiation
Begin copper repletion when serum copper is <8 μmol/L with or without elevated CRP, as this indicates definite deficiency requiring treatment. 1 Consider treatment when copper levels are <12 μmol/L with CRP >20 mg/L, though deficiency is less certain in this range. 1
Route Selection Algorithm
- In chronic, stable conditions with mild deficiency: Start with oral copper supplementation 1
- In severe deficiency or acute neurological deterioration: Use IV copper repletion 2
- The route choice depends on severity of copper deficit and clinical urgency 1
Treatment Dosing
Standard copper repletion requires 4-8 mg/day, which substantially exceeds the normal dietary requirement of 1.1-2 mg/day. 1 This higher dose is necessary to replete depleted stores and reverse neurological damage. 1
Important Dosing Caveat
Standard doses may be insufficient in some patients—one case required high-dose oral copper for relapsing myelopathy. 3 Monitor response and adjust dosing upward if neurological symptoms progress despite standard supplementation. 3
Critical Concurrent Interventions
Identify and eliminate the underlying cause simultaneously with copper supplementation:
- Remove excessive zinc sources (denture creams, supplements) as zinc competitively inhibits copper absorption 4, 5, 6
- Address malabsorption syndromes (celiac disease, inflammatory bowel disease) 4, 6
- Recognize that post-bariatric surgery patients require long-term monitoring as duodenal bypass permanently impairs copper absorption 4, 6
- Check for concomitant vitamin B12 deficiency as it can coexist and requires separate treatment 7
Expected Outcomes and Prognosis
Neurological recovery is often incomplete even with appropriate treatment—only 24% of patients showed improvement and only 5.1% recovered to baseline in a systematic review of 198 cases. 4 This underscores the critical importance of early diagnosis before irreversible neurological damage occurs. 4, 5
Copper supplementation typically:
- Normalizes hematological abnormalities (anemia, neutropenia, thrombocytopenia) reliably 6, 8
- Prevents further neurological deterioration in most cases 6, 8
- Provides variable degrees of actual neurological improvement 6, 8
- Requires months of treatment before maximal benefit is achieved 2
Rehabilitation Component
Intensive inpatient physical and occupational therapy should accompany copper repletion in patients with significant functional impairment. 2 One case demonstrated substantial functional improvement (ASIA C4 to C7 level) with combined copper supplementation and comprehensive rehabilitation including physiotherapy, hydrotherapy, and occupational therapy. 5, 2
Monitoring During Treatment
Measure serum copper and ceruloplasmin levels serially to confirm biochemical response. 1 In patients on parenteral nutrition or with ongoing risk factors (jejunostomy tubes, post-bariatric surgery), monitor copper levels every 6-12 months indefinitely. 1
Track zinc levels concurrently, as elevated zinc was found in 7 of 11 patients even when not considered the primary cause, suggesting zinc may contribute to copper deficiency more commonly than recognized. 6
Common Pitfalls to Avoid
- Do not delay treatment waiting for MRI confirmation—the characteristic inverted "V" T2 hyperintensity in dorsal columns appears in only 47% of cases 4, 6
- Do not assume surgical decompression will help—neurological deterioration progresses despite adequate decompressive surgery when copper deficiency is the underlying cause 4
- Do not discontinue treatment prematurely—copper stores require prolonged repletion, and one case developed relapsing myelopathy 40 years after jejunoileal bypass 2
- Do not overlook myelodysplastic syndrome misdiagnosis—cytopenias from copper deficiency may be incorrectly attributed to primary hematologic malignancy 6